FLGT (Fulgent Genetics) Total Current Assets : $326.5 Mil (As of Sep. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Fulgent Genetics Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Fulgent Genetics's total current assets for the quarter that ended in Sep. 2024 was $326.5 Mil.

Fulgent Genetics Total Current Assets Historical Data

The historical data trend for Fulgent Genetics's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fulgent Genetics Total Current Assets Chart

Fulgent Genetics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Current Assets

Get a 7-Day Free Trial

37.08

523.62

611.96

627.87

507.85

Fulgent Genetics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Current Assets	Get a 7-Day Free Trial															549.86	507.85	386.51	399.10	326.54

Fulgent Genetics Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Fulgent Genetics's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	424.154	+	57.445	+	5.827	+	20.419
	=	507.8

Fulgent Genetics's Total Current Assets for the quarter that ended in Sep. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	213.069	+	64.895	+	8.632	+	39.943
	=	326.5

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Fulgent Genetics (NAS:FLGT) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Fulgent Genetics's Liquidation Value for the quarter that ended in Sep. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	213.069	-	98.865	+	0.75 * 57.315	+	0.5 * 8.632
=	161.5

Fulgent Genetics Total Current Assets Related Terms

Thank you for viewing the detailed overview of Fulgent Genetics's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Fulgent Genetics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Fulgent Genetics Inc (NAS:FLGT) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

FLGT:Mexico 7F0:Germany

Address

4399 Santa Anita Avenue, El Monte, CA, USA, 91731

Website

https://www.fulgentgenetics.com

Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.

Executives

Hanlin Gao	10 percent owner, officer: Chief Scientific Officer	4399 SANTA ANITA AVE., EL MONTE CA 91731
Jian Xie	officer: Chief Operating Officer	C/O FULGENT GENETICS, INC., 4399 SANTA ANITA AVE, EL MONTE CA 91731
Ming Hsieh	director, 10 percent owner, officer: President and CEO	4399 SANTA ANITA AVE., EL MONTE CA 91731
Paul Kim	officer: CFO and Treasurer	4399 SANTA ANITA AVE, EL MONTE CA 91731
Regina E Groves	director	5751 COPLEY DRIVE, SAN DIEGO CA 92111
Leonard E Post	director
Michael Nohaile	director	C/O BIO AI ACCELERATION COMPANY, 20 UNIVERSITY AVENUE, CAMBRIDGE MA 02138
John C Bolger	director	4978 SANTA ANITA AVENUE, SUITE 205, TEMPLE CITY CA 91780
Ming Hsieh Trust	10 percent owner	4399 SANTA ANITA AVE., EL MONTE CA 91731
Linda Marsh	director	100 N. STONEMAN AVE., ROOM 200, ALHAMBRA CA 91801
Fulgent Genetics, Inc.	director	4399 SANTA ANITA AVE, EL MONTE CA 91731
Yun Yen	director	1301 OAKLAWN ROAD, ARCADIA CA 91006
James Mulay	director	6521 THOROUGHBRED LOOP, ODESSA FL 33556
Xi Long Usa, Inc.	10 percent owner	#6 XINRUI RD., SCIENCE CITY, LUOGANG DISTRICT, GUANGZHOU CITY F4 510663